Continuum Advisory LLC Purchases 360 Shares of Pfizer Inc. (NYSE:PFE)

Continuum Advisory LLC raised its holdings in Pfizer Inc. (NYSE:PFE) by 1.5% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,185 shares of the biopharmaceutical company’s stock after buying an additional 360 shares during the period. Continuum Advisory LLC’s holdings in Pfizer were worth $705,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. First Pacific Financial raised its position in shares of Pfizer by 28.2% in the second quarter. First Pacific Financial now owns 31,147 shares of the biopharmaceutical company’s stock valued at $871,000 after purchasing an additional 6,850 shares during the period. Raymond James Financial Services Advisors Inc. grew its stake in Pfizer by 7.4% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 2,415,955 shares of the biopharmaceutical company’s stock valued at $67,598,000 after buying an additional 166,281 shares during the last quarter. Sara Bay Financial raised its holdings in Pfizer by 10.5% in the 2nd quarter. Sara Bay Financial now owns 13,644 shares of the biopharmaceutical company’s stock valued at $382,000 after acquiring an additional 1,295 shares during the period. Milestone Asset Management LLC lifted its position in Pfizer by 154.7% during the second quarter. Milestone Asset Management LLC now owns 54,051 shares of the biopharmaceutical company’s stock worth $1,512,000 after acquiring an additional 32,827 shares during the last quarter. Finally, Means Investment CO. Inc. boosted its holdings in shares of Pfizer by 38.1% during the second quarter. Means Investment CO. Inc. now owns 41,373 shares of the biopharmaceutical company’s stock worth $1,158,000 after acquiring an additional 11,423 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

PFE has been the topic of a number of recent research reports. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Morgan Stanley upped their price target on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. Wells Fargo & Company lifted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Monday. Eight analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Price Performance

NYSE PFE traded up $0.21 on Tuesday, hitting $29.01. 3,550,721 shares of the company’s stock were exchanged, compared to its average volume of 39,257,094. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $37.19. The stock has a 50-day moving average of $28.76 and a 200-day moving average of $27.92. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The stock has a market cap of $164.39 billion, a price-to-earnings ratio of -480.25, a P/E/G ratio of 1.00 and a beta of 0.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. During the same period in the prior year, the business earned $0.67 earnings per share. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. Analysts expect that Pfizer Inc. will post 2.68 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 5.79%. The ex-dividend date is Friday, July 26th. Pfizer’s payout ratio is -2,800.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.